INmune Net Tangible Assets from 2010 to 2024

INMB Stock  USD 11.29  0.45  4.15%   
INmune Bio's Net Tangible Assets are increasing over the years with slightly volatile fluctuation. Overall, Net Tangible Assets are expected to go to about 52.6 M this year. Net Tangible Assets is the total assets of INmune Bio minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. View All Fundamentals
 
Net Tangible Assets  
First Reported
2017-12-31
Previous Quarter
38.8 M
Current Value
34.1 M
Quarterly Volatility
23.4 M
 
Covid
Check INmune Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among INmune main balance sheet or income statement drivers, such as Interest Expense of 1.6 M, Selling General Administrative of 6.4 M or Total Revenue of 147.2 K, as well as many exotic indicators such as Price To Sales Ratio of 1.2 K, Dividend Yield of 0.0 or PTB Ratio of 5.57. INmune financial statements analysis is a perfect complement when working with INmune Bio Valuation or Volatility modules.
  
This module can also supplement INmune Bio's financial leverage analysis and stock options assessment as well as various INmune Bio Technical models . Check out the analysis of INmune Bio Correlation against competitors.
For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.

Latest INmune Bio's Net Tangible Assets Growth Pattern

Below is the plot of the Net Tangible Assets of INmune Bio over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. INmune Bio's Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in INmune Bio's overall financial position and show how it may be relating to other accounts over time.
Net Tangible Assets10 Years Trend
Slightly volatile
   Net Tangible Assets   
       Timeline  

INmune Net Tangible Assets Regression Statistics

Arithmetic Mean16,050,167
Coefficient Of Variation148.24
Mean Deviation20,273,730
Median25,576
Standard Deviation23,793,541
Sample Variance566.1T
Range63.9M
R-Value0.82
Mean Square Error198.4T
R-Squared0.67
Significance0.0002
Slope4,370,012
Total Sum of Squares7925.9T

INmune Net Tangible Assets History

202452.6 M
202350.1 M
202243.6 M
202163.7 M
202022.2 M
20197.1 M
201825.6 K

About INmune Bio Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include INmune Bio income statement, its balance sheet, and the statement of cash flows. INmune Bio investors use historical funamental indicators, such as INmune Bio's Net Tangible Assets, to determine how well the company is positioned to perform in the future. Although INmune Bio investors may use each financial statement separately, they are all related. The changes in INmune Bio's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on INmune Bio's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on INmune Bio Financial Statements. Understanding these patterns can help to make the right decision on long term investment in INmune Bio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Tangible Assets50.1 M52.6 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether INmune Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of INmune Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inmune Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inmune Bio Stock:
Check out the analysis of INmune Bio Correlation against competitors.
For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Complementary Tools for INmune Stock analysis

When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Transaction History
View history of all your transactions and understand their impact on performance
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Is INmune Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.67)
Revenue Per Share
0.009
Quarterly Revenue Growth
(0.71)
Return On Assets
(0.27)
Return On Equity
(0.61)
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.